ArticleClinical kidney journal2026
Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proton pump inhibitors (PPIs) are associated with an increased risk of acute kidney injury and incident chronic kidney disease. Potassium-competitive acid blockers (P-CABs) have emerged as potent alternatives to PPIs, but their renal impact remains unclear. Methods: This study compared renal outcomes between P-CAB and PPI in patients receiving either PPIs or P-CABs at a tertiary referral hospital in Korea between 2019 and 2023. Renal outcomes were defined as creatinine doubling and a decline in estimated glomerular filtration rate (eGFR) ≥50%, termed as "eGFR decline." We used Cox proportional hazard analyses to adjust for multiple covariates. Results: The study included 1820 and 5121 patients in the P-CAB and PPI groups, respectively. The P-CAB group had lower incidences of creatinine doubling (13.4 vs 36.5, log-rank Conclusions: P-CABs showed a lower risk of renal function decline compared with PPIs, suggesting that P-CABs may be a safer alternative for long-term acid suppression. Further studies incorporating other P-CABs and PPIs are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.